NCT01882010View on ClinicalTrials.gov

Leukine (Sargramostim) for Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 1, 2013

Primary Completion Date

January 1, 2016

Study Completion Date

January 1, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

sargramostim

"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"

DRUG

placebo

saline solution daily subcutaneous injection 56 days

DIAGNOSTIC_TEST

Sham Comparator: Controls

Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.

Trial Locations (2)

68131

Neurology Consultants of Nebraska PC, Omaha

68198

University of Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Nebraska Neuroscience Alliance

UNKNOWN

lead

University of Nebraska

OTHER